Efficacy and safety of cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real-world experience

被引：1

作者：

Peng, Tzu-Rong ^{[1
]}

Chen, Jia-Hui ^{[2
,3
]}

Wu, Ta-Wei ^{[1
]}

机构：

[1] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Pharm, 289 Jianguo Rd, New Taipei City 23142, Taiwan

[2] Buddhist Tzu Chi Med Fdn, Taipei Tzu Chi Hosp, Dept Surg, Div Gen Surg, 289 Jianguo Rd, New Taipei City 23142, Taiwan

[3] Buddhist Tzu Chi Univ, Sch Med, Hualien, Taiwan

来源：

THORACIC CANCER | 2023年 / 14卷 / 30期

关键词：

cyclin-dependent kinase inhibitor; advanced breast cancer; efficacy; safety; PALBOCICLIB; FULVESTRANT; MULTICENTER; LETROZOLE;

D O I：

10.1111/1759-7714.15090

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) have been shown to improve progression-free survival (PFS) in patients with metastatic breast cancer (MBC) in randomized control trials. This study aimed to evaluate the efficacy and safety of CDK4/6i in patients with advanced breast cancer (ABC) in a clinical setting. Methods: Consecutive patients with ABC were treated between October 2019 and March 2023 at Taipei Tzu Chi Hospital, Taiwan. Patients who had received at least one dose of CDK4/6i were included in this retrospective study. The main outcome of this study was efficacy based on the treating physicians' assessments in terms of PFS, and overall survival (OS), as well as the factors associated with patient outcome. The secondary outcome was safety. Results: A total of 85 patients were included in the analysis, with a mean age of 66.8 years. After a median follow-up of 16.1 months, the median PFS was 28.4 months (95% CI: 22.5-33.6) and the median OS could not yet be estimated. The most common adverse events (AE) were fatigue (50.8%), anorexia (45.9%), and leukopenia (44.7%). In multivariable analysis, treatment with CDK4/6i with any grade AE or response to treatment effect (CR/PR) was an independent predictor for longer PFS (hazard ratio [HR] = 0.27, 95% CI: 0.11-0.68; HR = 0.21, 95% CI: 0.06-0.67; p < 0.05). Conclusion: CDK4/6i administered in a real-world setting exhibits a similar survival benefit with the clinical trials.

引用

页码：3012 / 3019

页数：8

共 27 条

[1] Neoadjuvant palbociclib on ER plus breast cancer (N007): clinical response and EndoPredict's value [J].

Chow, Louis W. C. ;

Morita, Satoshi ;

Chow, Christopher Y. C. ;

Ng, Wai-Kuen ;

Toi, Masakazu .

[2] Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer [J].

Cottu, P. ;

D'Hondt, V. ;

Dureau, S. ;

Lerebours, F. ;

Desmoulins, I. ;

Heudel, P-E ;

Duhoux, F. P. ;

Levy, C. ;

Mouret-Reynier, M-A ;

Dalenc, F. ;

Frenel, J-S ;

Jouannaud, C. ;

Venat-Bouvet, L. ;

Nguyen, S. ;

Ferrero, J-M ;

Canon, J-L ;

Grenier, J. ;

Callens, C. ;

Gentien, D. ;

Lemonnier, J. ;

Vincent-Salomon, A. ;

Delaloge, S. .

ANNALS OF ONCOLOGY, 2018, 29 (12) :2334-2340

[3] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].

Cristofanilli, Massimo ;

Turner, Nicholas C. ;

Bondarenko, Igor ;

Ro, Jungsil ;

Im, Seock-Ah ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Loi, Sherene ;

Verma, Sunil ;

Iwata, Hiroji ;

Harbeck, Nadia ;

Zhang, Ke ;

Theall, Kathy Puyana ;

Jiang, Yuqiu ;

Bartlett, Cynthia Huang ;

Koehler, Maria ;

Slamon, Dennis .

LANCET ONCOLOGY, 2016, 17 (04) :425-439

[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5] Palbociclib and Letrozole in Advanced Breast Cancer [J].

Finn, Richard S. ;

Martin, Miguel ;

Rugo, Hope S. ;

Jones, Stephen ;

Im, Seock-Ah ;

Gelmon, Karen ;

Harbeck, Nadia ;

Lipatov, Oleg N. ;

Walshe, Janice M. ;

Moulder, Stacy ;

Gauthier, Eric ;

Lu, Dongrui R. ;

Randolph, Sophia ;

Dieras, Veronique ;

Slamon, Dennis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936

[6] CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis [J].

Gao, Jennifer J. ;

Cheng, Joyce ;

Bloomquist, Erik ;

Sanchez, Jacquelyn ;

Wedam, Suparna B. ;

Singh, Harpreet ;

Amiri-Kordestani, Laleh ;

Ibrahim, Amna ;

Sridhara, Rajeshwari ;

Goldberg, Kirsten B. ;

Theoret, Marc R. ;

Kluetz, Paul G. ;

Blumenthal, Gideon M. ;

Pazdur, Richard ;

Beaver, Julia A. ;

Prowell, Tatiana M. .

LANCET ONCOLOGY, 2020, 21 (02) :250-260

[7] Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer [J].

Garcia-Trevijano Cabetas, M. ;

Lucena Martinez, P. ;

Jimenez Nacher, I. ;

Diaz Almiron, M. ;

Zamora Aunon, P. ;

Herrero Ambrosio, A. .

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (04) :893-899

[8]

Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]

[9] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer [J].

Hortobagyi, G. N. ;

Stemmer, S. M. ;

Burris, H. A. ;

Yap, Y. S. ;

Sonke, C. S. ;

Paluch-Shimon, S. ;

Campone, M. ;

Petrakova, K. ;

Blackwell, K. L. ;

Winer, E. P. ;

Janni, W. ;

Verma, S. ;

Conte, P. ;

Arteaga, C. L. ;

Cameron, D. A. ;

Mondal, S. ;

Su, F. ;

Miller, M. ;

Elmeliegy, M. ;

Germa, C. ;

O'Shaughnessy, J. .

ANNALS OF ONCOLOGY, 2018, 29 (07) :1541-1547

[10] Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer [J].

Im, S. -A. ;

Lu, Y. -S. ;

Bardia, A. ;

Harbeck, N. ;

Colleoni, M. ;

Franke, F. ;

Chow, L. ;

Sohn, J. ;

Lee, K. -S. ;

Campos-Gomez, S. ;

Villanueva-Vazquez, R. ;

Jung, K. -H. ;

Chakravartty, A. ;

Hughes, G. ;

Gounaris, I. ;

Rodriguez-Lorenc, K. ;

Taran, T. ;

Hurvitz, S. ;

Tripathy, D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :307-316

← 1 2 3 →